BioNTech is a Germany-based biotechnology company focused on developing immunotherapies and vaccines, with a core expertise in messenger RNA (mRNA) technologies. Founded in 2008 and headquartered in Mainz, the company’s R&D spans individualized cancer therapies, prophylactic vaccines for infectious diseases, cell therapies, and engineered antibodies. BioNTech is publicly listed on the Nasdaq (ticker: BNTX).
For the chemical and bioprocessing value chain, BioNTech operates GMP-compliant capabilities in mRNA synthesis, lipid nanoparticle formulation, and sterile fill–finish, supported by in‑house analytics and quality systems. Its platform work links nucleic acid chemistry, lipid excipient design, and scalable biomanufacturing to deliver nucleic-acid–based medicines. The company collaborates with global pharmaceutical partners and maintains a clinical pipeline across oncology and infectious disease indications, leveraging platform approaches to accelerate development and production.
Phase Ib/II trial will test DLL3/CD3 T‑cell engager plus PD‑L1/VEGF‑A bispecific in extensive‑stage SCLC to boost durable antitumor immunity; dosing to start H2 2026
€95M in funding will support an mRNA vaccine site in Rwanda, boosting Africa's vaccine production and health innovation.
The acquisition adds 290 skilled professionals and supports AI-driven drug discovery. InstaDeep will continue serving global clients in various sectors as a UK-based subsidiary. Total deal value: €500 million.
The collaboration will leverage AI and ML to advance drug discovery, protein engineering, and supply chain optimization, focusing on novel mRNA-based vaccines and therapeutics for cancer and infectious diseases.
